S-CUBE
Phase 3
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-jRCT2080220889
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1)Patients who are able to do oral administration
2)Patients who have the history of histologically and cytologically confirmed primary hepatocellular carcinoma.
3)Hepatocellular carcinoma patients who are failure to sorafenib monotherapy.
4)Life expectancy of 60 days or more following the start of treatment
5)Patients with written informed consent.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival
- Secondary Outcome Measures
Name Time Method